- United States
- /
- Medical Equipment
- /
- NYSE:GKOS
3 Stocks That May Be Trading Below Their Estimated Value By Up To 50%
The United States market has shown resilience with a 1.7% increase over the last week and a robust 20% rise over the past year, while earnings are projected to grow by 17% annually. In such an environment, identifying stocks that may be trading below their estimated value can present opportunities for investors seeking to capitalize on potential growth at a discounted price.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Tempus AI (TEM) | $54.29 | $107.98 | 49.7% |
| OceanFirst Financial (OCFC) | $19.48 | $38.00 | 48.7% |
| Natera (NTRA) | $310.78 | $606.27 | 48.7% |
| HBT Financial (HBT) | $37.22 | $73.33 | 49.2% |
| HawkEye 360 (HAWK) | $24.37 | $48.05 | 49.3% |
| Haemonetics (HAE) | $90.38 | $177.01 | 48.9% |
| Goosehead Insurance (GSHD) | $67.40 | $134.62 | 49.9% |
| Glaukos (GKOS) | $189.45 | $378.76 | 50% |
| Fluence Energy (FLNC) | $13.22 | $25.69 | 48.5% |
| Advanced Energy Industries (AEIS) | $329.54 | $653.62 | 49.6% |
Underneath we present a selection of stocks filtered out by our screen.
Datadog (DDOG)
Overview: Datadog, Inc. operates an observability and security platform for cloud applications globally, with a market cap of approximately $86.50 billion.
Operations: The company generates revenue primarily from its IT Infrastructure segment, which amounts to $3.97 billion.
Estimated Discount To Fair Value: 20.8%
Datadog's recent earnings report shows strong growth, with Q2 sales reaching US$1.12 billion, up from US$826.76 million a year ago. The company is trading at 20.8% below its estimated future cash flow value of US$318.35 per share, indicating potential undervaluation based on cash flows. Despite significant insider selling recently, Datadog's earnings are expected to grow significantly faster than the broader market over the next three years.
- Upon reviewing our latest growth report, Datadog's projected financial performance appears quite optimistic.
- Click to explore a detailed breakdown of our findings in Datadog's balance sheet health report.
Super Micro Computer (SMCI)
Overview: Super Micro Computer, Inc. develops and sells server and storage solutions based on modular and open-standard architecture globally, with a market cap of approximately $24.33 billion.
Operations: The company's revenue is primarily driven by its development and provision of high-performance server solutions, amounting to $39.06 billion.
Estimated Discount To Fair Value: 17.2%
Super Micro Computer's recent earnings report highlights strong financial performance, with Q4 sales at US$11.12 billion, nearly doubling from the previous year. The stock trades at US$39.16, below its estimated future cash flow value of US$47.31, suggesting it is undervalued based on cash flows. However, legal challenges related to patent infringements could pose risks. Despite these issues, the company's revenue growth is expected to outpace the market significantly over the next year.
- The growth report we've compiled suggests that Super Micro Computer's future prospects could be on the up.
- Unlock comprehensive insights into our analysis of Super Micro Computer stock in this financial health report.
Glaukos (GKOS)
Overview: Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that develops therapies for glaucoma, corneal disorders, and retinal diseases globally, with a market cap of approximately $11 billion.
Operations: The company's revenue segment focuses on the development and commercialization of ophthalmic therapies, generating $612.84 million.
Estimated Discount To Fair Value: 50%
Glaukos Corporation's stock is trading at US$189.45, significantly below its estimated future cash flow value of US$378.76, indicating it is undervalued based on cash flows. The company recently raised its 2026 net sales guidance to between US$680 million and US$700 million and reported Q2 sales of US$185.61 million, up from the previous year. Although still incurring losses, Glaukos is expected to become profitable within three years with above-average market growth.
- Our comprehensive growth report raises the possibility that Glaukos is poised for substantial financial growth.
- Navigate through the intricacies of Glaukos with our comprehensive financial health report here.
Where To Now?
- Delve into our full catalog of 140 Undervalued US Stocks Based On Cash Flows here.
- Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
mitchell_lawlerMicron (MU) is booming, and it still doesn't look ‘expensive’ based on next year's earnings. So why does our own valuation say it could be worth 40% less?
About NYSE:GKOS
Glaukos
An ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
Excellent balance sheet with reasonable growth potential.
Similar Companies
Market Insights
Weekly Picks

The 1960s Fighter Jet That Could Crack Open a $20 Billion Satellite Market

The Short and Long Term Compounder of Liquid Cooling industry.

I Fell in Love With a Data-Center Cooling Stock. Then I Opened the Filings.

The Cheap Genius Problem
Recently Updated Narratives

High rates continues for Q4 '26 - Q1 '27

A Case for Salazar Resources to reach CAD $2.50 - $7.50+ by 2030

Why I Invest in SIPEF?
Popular Narratives

